Nasdaq:BLFS
BIOLIFE SOLUTIONS INC
A US-based biotech firm advancing proprietary therapeutic candidates for serious diseases through a focused R&D pipeline and strategic licensing model.
Key Metrics
Investment Thesis
Bull Case
Investors might consider BLFS due to its improving loss trajectory and strong cash flow from operations which supports continued R&D without immediate dilution. The strategic divestiture of $23.5M in assets provides liquidity that can be redeployed into high-potential pipeline candidates or new partnerships. Additionally, the company's clean balance sheet with no long-term debt offers a resilient foundation for navigating the challenging early-stage biotech market.
Bear Case
The stock faces headwinds from significant revenue contraction over the past three years and a persistent net loss that erodes shareholder value. High operating expenses coupled with a massive retained earnings deficit suggest the company is still in a capital-intensive growth phase with no immediate path to profitability. Investors should also be wary of the volatile cash flow situation where investing outflows far exceed operational inflows, potentially requiring continuous equity fundraising.
About BIOLIFE SOLUTIONS INC
Biolife Solutions Inc. (BLFS) is a biotechnology company focused on developing innovative therapies for serious diseases, primarily operating in the United States and internationally markets. The company leverages its proprietary technology platforms to advance clinical candidates aimed at addressing unmet medical needs in oncology and rare disorders. Key revenue streams include product sales from commercialized assets, strategic licensing agreements, and potential milestone payments from partnership collaborations.
Analysis
Management Discussion
Recent financial performance shows a narrowing net loss trend from -$139.8M in 2022 to -$4.6M in 2025, indicating improving operational efficiency despite lower overall revenue. The company successfully managed cash flow from operations at $20.1M while utilizing significant cash reserves and divestiture proceeds to fund investing activities totaling $71.5M. However, the substantial retained earnings deficit of -$339.7M highlights the long-term capital requirements typical of biotechnology development phases.
Industry Overview
The biotechnology sector is characterized by high innovation risk and rapid technological advancement, with companies focusing on specialized therapies for niche patient populations. Market leaders often rely on strategic licensing and partnership deals to offset the high costs of bringing new drugs to market before achieving full commercialization. Regulatory environments remain stringent, requiring substantial investment in clinical trials to secure approval for novel mechanisms of action.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $161.8M | $143.3M | $82.3M | $96.2M |
| Cost of Revenue | $0 | $0 | $0 | $34.1M |
| Gross Profit | $161.8M | $143.3M | $82.3M | $62.1M |
| Operating Expenses | $307.3M | $214.1M | $89.4M | $78.7M |
| Operating Income | $-145.5M | $-70.8M | $-7.1M | $-16.6M |
| R&D | $14.8M | $18.8M | $7.9M | $7.6M |
| G&A | $47.7M | $55.7M | $40.5M | $45.5M |
| Marketing | $21.6M | $24.6M | $9.6M | $9.8M |
| Stock-Based Comp | $25.3M | $31.7M | $30.9M | $23.0M |
| D&A | $6.8M | $7.1M | $5.2M | $2.3M |
| Depreciation | $3.3M | $3.6M | $700.0K | $800.0K |
| Amortization | $9.7M | $5.2M | $2.7M | $263.0K |
| Other OpEx | $223.3M | $115.0M | $31.3M | $15.8M |
| Non-Operating Income | $714.0K | $4.6M | $-4.3M | $4.5M |
| Pre-Tax Income | $-144.8M | $-66.3M | $-11.4M | $-12.1M |
| Income Tax | $-5.0M | $169.0K | $-38.0K | $49.0K |
| Continuing Ops | $-139.8M | $-66.4M | $-11.4M | $-12.1M |
| Discontinued Ops | $0 | $0 | $-8.8M | $7.5M |
| Net Income | $-139.8M | $-66.4M | $-20.2M | $-4.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-139.8M | $-66.4M | $-20.2M | $-4.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $138.5M | $120.6M | $148.8M | $136.6M |
| Cash & Equivalents | $19.4M | $35.4M | $95.4M | $33.0M |
| Accounts Receivable | $33.9M | $18.7M | $9.2M | $8.0M |
| Inventory | $34.9M | $43.5M | $29.0M | $30.2M |
| Prepaid Expenses | $6.9M | $6.8M | $6.0M | $9.5M |
| Other Current Assets | $43.3M | $16.3M | $9.2M | $55.9M |
| Long-Term Assets | $311.8M | $292.1M | $250.7M | $269.3M |
| PP&E (Net) | $23.6M | $21.1M | $6.1M | $14.7M |
| Intangibles | $32.1M | $21.1M | $9.6M | $4.3M |
| Goodwill | $224.7M | $224.7M | $212.3M | $208.6M |
| Operating Leases | $15.3M | $11.4M | $10.7M | $7.5M |
| Other LT Assets | $16.0M | $13.7M | $11.1M | $34.3M |
| Total Assets | $450.2M | $412.7M | $399.5M | $405.9M |
| Current Liabilities | $44.6M | $42.2M | $32.7M | $23.0M |
| Accounts Payable | $15.4M | $6.9M | $3.6M | $1.5M |
| Current Debt | $1.8M | $6.8M | $10.9M | $5.0M |
| Current Leases | $2.9M | $2.8M | $1.5M | $2.2M |
| Deferred Revenue | $548.0K | $661.0K | $103.0K | $195.0K |
| Taxes Payable | $975.0K | $562.0K | $0 | — |
| Other Current Liab | $19.9M | $17.5M | $9.5M | $8.2M |
| Long-Term Liabilities | $41.5M | $32.9M | $17.8M | $11.0M |
| Long-Term Debt | $23.8M | $18.3M | $5.0M | $0 |
| LT Operating Leases | $15.0M | $13.2M | $12.7M | $10.7M |
| Other LT Liab | $2.7M | $1.4M | $124.0K | $360.0K |
| Total Liabilities | $86.0M | $75.1M | $50.6M | $34.0M |
| Shareholders' Equity | $364.2M | $337.7M | $348.9M | $371.9M |
| Retained Earnings | $-246.9M | $-313.3M | $-335.1M | $-339.7M |
| AOCI | $-679.0K | $-345.0K | $24.0K | $132.0K |
| Total L&E | $450.2M | $412.7M | $399.5M | $405.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-139.8M | $-66.4M | $-20.2M | $-4.6M |
| Non-Cash Adjustments | $110.5M | $65.7M | $25.3M | $27.6M |
| Working Capital Changes | $20.8M | $-11.8M | $3.3M | $-2.9M |
| Cash from Operations | $-8.5M | $-12.5M | $8.4M | $20.1M |
| Capital Expenditures | $10.4M | $6.4M | $3.2M | $9.5M |
| Cash from Investing | $-58.1M | $17.8M | $58.3M | $-71.5M |
| Cash from Financing | $16.3M | $10.6M | $-6.8M | $-10.9M |
| FX Effect | $-108.0K | $35.0K | $0 | $0 |
| Net Change in Cash | $-50.3M | $15.9M | $59.9M | $-62.3M |
| Beginning Cash | $69.9M | $19.5M | $35.4M | $95.4M |
| Ending Cash | $19.5M | $35.4M | $95.4M | $33.0M |
Frequently Asked Questions
How does BIOLIFE SOLUTIONS INC make money?
1) Commercial Product Sales: Revenue generated from the sale of approved therapeutics and related medical products, evidenced by cost of revenue and gross profit figures. 2) Licensing and Collaboration: Income derived from strategic partnerships, including significant divestitures indicating asset monetization or milestone payments. 3) Research and Development: Internal investment in discovering and developing new therapeutic candidates, reflected in substantial R&D expenditures relative to total revenue.
What are the main risks for BLFS?
1) Clinical Development Uncertainty: High failure rates in late-stage clinical trials could result in significant write-downs or cessation of programs without commercial return. 2) Revenue Volatility: The company's reliance on licensing deals and divestitures leads to unpredictable revenue streams, as seen in the sharp decline from 2022 to 2024. 3) Cash Burn Rate: Persistent net losses and high operating expenses pose a risk of liquidity constraints if financing markets tighten or fundraising efforts stall. 4) Regulatory Challenges: Delays in regulatory approvals for new therapies could impact timelines to market, affecting valuation multiples and investor confidence.
What is BLFS's competitive advantage?
1) Proprietary Technology Platforms: The company possesses unique scientific approaches that differentiate its drug discovery and development pipeline from competitors. 2) Strategic Asset Portfolio: A diverse portfolio of clinical-stage assets provides multiple potential pathways for commercialization or exit via licensing deals. 3) Efficient Capital Structure: With zero long-term debt and a positive working capital position, the firm maintains financial flexibility to navigate early-stage development risks.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.